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Systemic lupus erythematosus (SLE) is a complex and unpredictable disease which varies
greatly among patients and has a significant impact on an individual’s daily living and quality
of life. A better understanding of the patients’ experiences with the disease is vital to the
effective management of the disease. LUPUS UK, a national UK-registered charity support-
ing people with systemic and discoid lupus, conducted a UK-wide survey of individuals living
with lupus in order to provide foundation information to support and identify gaps needing
further research.
An anonymous survey was sent to 5660 LUPUS UK members in order to obtain demo-
graphic, diagnosis, symptom and treatment information. A total of 2527 surveys were
returned by 2371 females (mean age 56.9 years, SD 13.6) and 156 males, (mean age 60.9
years, SD 15.7). Individuals reported a mean (SD) time to diagnosis from the first symptom
of 6.4 (9.5) years, with 47% (n¼ 1186) initially being given a different diagnosis prior to lupus.
Fatigue/weakness (91%, n¼ 2299) and joint pain/swelling (77.4%, n¼ 1957) were the most
common symptoms that interfere with daily activities, while 73% (n¼ 1836) noted having
some problems that make them unable to carry out their usual daily activities. Thirty-two
per cent (n¼ 806) were also seeking support beyond traditional pharmacological treatments,
such as acupuncture and massage. This study highlights the range and frequency of symptoms
difficult to live with on a daily basis and support areas needing further research to improve
patients’ well-being. Lupus (2018) 27, 681–687.
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Introduction
Systemic lupus erythematosus (SLE) is a multisys-
tem inflammatory disease caused by dysregulation
of the immune system with contribution from gen-
etic, hormonal and environmental factors. The dis-
ease mainly affects young females, with a 9:1 ratio
of those diagnosed being female.1 SLE is more
prevalent in people of African ancestry as well as
Indo-Asians and individuals from the Far East
such as China.2
Diagnosing SLE can be difficult due to the com-
plex and unpredictable disease course, as well as the
evolution of clinical features developing over time.
In general, there is also no single measure that can
confirm the diagnosis.3Whilst some individuals may
be mildly affected, others can experience severe
relapses of life-threatening disease. Early recogni-
tion of SLE can lead to better treatment and pre-
ventive care, thereby avoiding the more severe and
long-standing outcomes such as renal impairment,
cardiovascular disease, and infections.4 Quality of
life and the individual personal burden of SLE are
equally important to allow us to better understand
the illness from the patient’s perspective. Symptoms
of SLE include pain, fatigue, sleep disturbances,
depression and psychological disorders with consid-
erable emotional adjustment often required.5 Whilst
health care providers may focus more on symptoms
and signs that reflect specific organ involvement
and/or damage and other co-morbidities, patients
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often highlight more the symptoms that affect their
everyday lives.6 The measurement of outcomes and
experiences with the disease from the patient’s per-
spective is clinically meaningful6 and therefore it is
essential to consider when planning services and
developing a research agenda.
Further insight is needed into the personal
burden of SLE in everyday living and to identify
areas of unmet need from the patient’s perspective.
LUPUS UK, a national United Kingdom (UK)-
registered charity supporting people with systemic
and discoid lupus, performed a nationwide survey
of lupus and individuals with manifestations of
lupus to provide foundation information to identify
gaps needing further research and to give a better
overall understanding of the personal impact of
living with SLE in the UK.
Methods
Survey population and data collection
LUPUS UK developed a survey questionnaire in
collaboration with The Arthritis Research UK
Centre for Epidemiology, University of
Manchester (see Appendix 1 in supplementary
material). Survey questions included: month and
year of birth, gender, ethnicity (based on Office
for National Statistics 2011 Census for England
and Wales), living status and where applicable,
details of work status and benefit support.
Individuals were asked details of their consultant
diagnosis(es) including month and year and details
of other diagnoses they may have previously been
given for this condition. Participants were asked to
indicate the symptoms that regularly affect them,
those they found more difficult to live with and
conditions making their symptoms worse, such as
sunlight, cold/damp, fatigue and stress.
Information on general health including problems
with mobility, self-care, anxiety/depression, pain
and fatigue and level of disruption to undertake
usual activities were also indicated. The level of
support individuals received and any beneficial
treatment including both prescribed and alternative
therapies were also noted. Ethical approval from
the local ethics committee was confirmed not to
be required given the anonymous methods of data
collection and transfer to the university.
Statistical methods
The demographic and survey responses were sum-
marized using descriptive statistics expressed as
mean standard deviation (SD) or as percentages
where appropriate using STATA 13.
Results
Demographic characteristics
The survey was mailed to 5660 registered members
of LUPUS UK, of whom 44.6% (n¼ 2527) were
completed and returned. Of respondents, 93.8%
(n¼ 2371) were female and 6.2% (n¼ 156) were
male, with a mean (SD) age at survey date of 56.9
(13.6) years and 60.9 (15.7) years, respectively. The
majority of the respondents were of White British
ethnicity (93%, n¼ 2350) with 2.7% (n¼ 68) and
1.8% (n¼ 46) of African and Indo-Asian origin,
respectively. Regarding home circumstances,
78.9% (n¼ 1994) lived with their partner or
family and 19.4% (n¼ 489) lived alone (supplemen-
tary Table 1). Only 15% (n¼ 378) of individuals
worked full time with 51.1% (n¼ 1291) receiving
some form of benefits and the majority having
retired (52.8%, n¼ 1335). Of retirees, 44.0%
(n¼ 587) had retired on medical grounds (supple-
mentary Table 2).
Diagnosis characteristics
Patients could indicate what main diagnosis(es)
they had been given. The most frequent diagnosis
was SLE (88%) with 68.3% having SLE as their
sole diagnostic term. Other reported additional
diagnoses or aspects of their disease included dis-
coid lupus (10.6%), ‘connective tissue disease’
(CTD) (11.7%), lupus nephritis (9.5%) and anti-
phospholipid syndrome (APS)/Hughes’ syndrome
(9.7%) (supplementary Table 3).
The mean (SD) reported time from the first
‘lupus’ symptom to diagnosis was 6.4 (9.5) years
(Table 1). This mean (SD) time was shorter in
men (4.8 (8.7) years) (Table 1) and Black patients
(2.8 (3.6) years) (supplementary Table 4).
Examining the time to diagnosis by decade of
when the diagnosis was made, no trend was
observed, indicating no temporal trend towards
earlier time to diagnosis in recent decades (Table 1).
One-half of respondents had been given a differ-
ent diagnosis prior to their final diagnosis (46.9%,
n¼ 1186). The most common were rheumatoid
arthritis (RA; 36.7%, n¼ 435), chronic fatigue
(16.1%, n¼ 191), ‘skin disorders’ (11.2%, n¼ 133)
and a chronic psychological disorder (10.8%,
n¼ 128). In total, chronic fatigue, fibromyalgia
and psychological problems contributed to almost
one-third (26.9%, n¼ 319) of all prior diagnoses
(supplementary Tables 5 and 6).
The commonest co-morbidities reported were
thyroid disease (12.9%, n¼ 326), overlapping RA
(11.2%, n¼ 283), osteoporosis (9.0%, n¼ 227),
osteoarthritis (10.1%, n¼ 256) and cardiac condi-
tions (11.5%, n¼ 291) (supplementary Table 7).
Symptoms experienced
A total of 53.8% (n¼ 1360) patients reported
suffering frequently from between 6 and 10 differ-
ent symptoms. Fatigue and weakness were experi-
enced by 91.0% (n¼ 2299) of the group and 77.4%
(n¼ 1957) had regular joint pain or swelling
(Figure 1). When asked to rank the top three
symptoms most difficult to live with, these first
two symptoms were also ranked in their ‘top
three’ by 80.9% (n¼ 2044) and 60.4% (n¼ 1527)
of individuals, respectively (supplementary Tables
8 and 9).
Conditions reported to make lupus worse both in
males and females were over-exertion and fatigue
(males; 96.2% n¼ 108, females; 82.6%, n¼ 1959),
followed by stress and worry (males; 52.6% n¼ 82,
females; 75.2% n¼ 1784,), sunlight (males; 43%
n¼ 67, females; 57.6% n¼ 1365), and cold and
damp conditions (males; 44.8% n¼ 70, females;
56.2% n¼ 1333) (supplementary Table 10).
General health indicators on the day of
the survey also suggested poor health of the
group, with 19.7% (n¼ 498) having problems walk-
ing or being in a wheelchair, 27.3% (n¼ 689)
reporting extreme pain and discomfort, 19.9%
(n¼ 502) experiencing extreme anxiety or depres-
sion and 72.7% (n¼ 1836) having some prob-
lems or unable to carry out their usual activities
(Table 2).
Figure 1 Most frequently reported symptoms to suffer from stratified by total number of participants experiencing a symptom
and number of participants ranking symptoms in the top three of most difficult symptoms to live with.
Table 1 Self-reported time to diagnosis from first symptom by decade of diagnosis
Time to diagnosis
(years)
mean (SD)
Pre-1990 (n¼ 461) 1990–1999 (n¼ 737) 2000–2009 (n¼ 772) 2010–2014 (n¼ 350) Total (n¼ 2320)
5.8 (7.9) 6.5 (9.9) 6.5 (10.1) 6.4 (8.8) 6.4 (9.5)
Males Females Males Females Males Females Males Females Males Females
5.5 (9.1) 5.8 (7.8) 5.2 (10.7) 6.6 (9.8) 3.9 (6.5) 6.7 (10.4) 4.4 (6.7) 6.5 (8.9) 4.8 (8.7) 6.5 (9.5)
Health care and support
In 82.5% (n¼ 2085) of individuals, their rheuma-
tologist was reported as their current lead health
care professional for clinical management, with
16.9% (n¼ 426) and 11.3% (n¼ 285) seeing a
dermatologist and nephrologist, respectively (sup-
plementary Table 11). Using a visual analogue
scale, patients reported high levels of day-to-day
support from their partners, family and friends in
addition to their treating consultant (Table 3).
Treatment
Patients self-reported high levels of therapy use
with the commonest being glucocorticoids (67%,
n¼ 1694) and anti-malarials (67.9%, n¼ 1715)
with 45.1% (n¼ 1140) also taking immunosuppres-
sants (Table 4).
Regarding alternative or complementary thera-
pies, 32% (n¼ 806) accessed these, with acu-
puncture and massage being the most common
(14.9%, n¼ 120 and 13.8%, n¼ 111, respectively)
(Figure 2).
Discussion
This UK-wide survey of individuals living with
SLE provides important insights into the personal
burden of the disease in everyday living and high-
lights areas for further research. First, we found
there was a significant period of time (6.4 years)
between initial symptoms and reaching the diagno-
sis of SLE. Almost one-half (46.9%) of the individ-
uals who responded had also been given a different
initial diagnosis prior to their final diagnosis. In
addition, we found no change in this time to diag-
nosis over recent decades despite wider awareness
of the condition and efforts to improve the identi-
fication and diagnosis of SLE. Of interest, the time
to diagnosis was much shorter in Black patients
(2.8 years). This may reflect the higher incidence
and better awareness amongst health care profes-
sionals of the possibility of SLE in Black individ-
uals and also since the initial presentation in this
population may be more severe, a more prompt
diagnosis is also more likely. We also noted a
trend towards a shorter time to diagnosis in men
(4.8 years). Men in the UK are known to have
lower primary care consultation rates than
Table 2 General health indicators on the day of survey
completion
General health variable n (%)
Men
n¼ 156
Women
n¼ 2371
Total
n¼ 2527
Mobility
No problems 59 (37.8) 892 (37.6) 951 (37.6)
Some problems 57 (36.5) 974 (41.1) 1031 (40.8)
Problem walking/in wheelchair 37 (36.5) 461 (19.4) 498 (19.7)
Housebound 1 (0.6) 32 (1.4) 33 (1.3)
Self-care
No problems 111 (71.2) 1540 (65.0) 1651 (65.3)
Some problems 39 (25.0) 715 (30.2) 754 (29.8)
Unable to/extreme 5 (3.2) 93 (3.9) 98 (3.9)
Carry out usual activities
No problems 56 (35.9) 665 (28.1) 721 (28.5)
Some problems 72 (46.2) 1271 (53.6) 1343 (53.2)
Unable to/extreme 26 (16.7) 423 (17.8) 449 (17.8)
Problems with pain/discomfort
No problems 31 (19.9) 240 (10.1) 271 (10.7)
Some problems 91 (58.3) 1464 (61.8) 1555 (61.5)
Unable to/extreme 32 (20.5) 657 (27.7) 689 (27.3)
Anxiety/depression
No problems 54 (34.6) 575 (24.3) 629 (24.9)
Some problems 64 (41.0) 1270 (53.6) 1334 (52.8)
Unable to/extreme 29 (18.6) 473 (20.0) 502 (19.9)
Pain from lupus in past week
(VAS 0–10) mean (SD)
3.7 (3.0) 4.8 (2.8) 4.7 (2.9)
Fatigue from lupus in past week
(VAS 0–10) mean (SD)
5.1 (3.3) 6.4 (2.7) 6.3 (2.8)
VAS: visual analogue scale.
Table 3 Support an individual received (VAS scale 0–10) by
gender group
Support mean (SD)
Men
n¼ 156
Women
n¼ 2371
Total
n¼ 2527
Partner 9.0 (2.4) 7.9 (3.1) 7.2 (3.2)
Consultant 8.1 (2.8) 7.6 (2.7) 7.7 (2.7)
Family 7.6 (3.6) 7.2 (3.2) 7.2 (3.2)
Friends 5.9 (3.7) 6.3 (3.2) 6.3 (3.3)
GP 6.8 (3.2) 6.2 (3.4) 6.2 (3.4)
Other specialist 6.1 (3.8) 5.5 (3.8) 5.5 (3.8)
Specialist nurse 5.9 (3.8) 5.2 (4.0) 5.3 (4.0)
LUPUS groupa 4.7 (3.8) 5.2 (3.8) 5.2 (3.8)
aExcluding those indicating did not use.
VAS: visual analogue scale; GP: general practitioner.
Table 4 Frequency of self-reported medication use by gender
Medication n (%)
Men
n¼ 156
Women
n¼ 2371
Total
n¼ 2527
Steroids 96 (61.5) 1598 (67.4) 1694 (67.0)
Anti-malarials 91 (58.3) 1624 (68.5) 1715 (67.9)
Immunosuppressant 77 (49.4) 1063 (44.8) 1140 (45.1)
Biologics 11 (7.1) 117 (4.9) 128 (5.1)
Non-steroidals 48 (30.8) 859 (36.2) 907 (35.9)
Other medication 31 (19.9) 433 (18.3) 464 (18.4)
Alternative therapy 14 (9.0) 460 (19.4) 474 (18.8)
women7 and we hypothesize that men may also
present with more definite and/or severe symptoms
thus prompting earlier referral and diagnosis.
The diagnosis and early recognition of a multi-
system disease such as this is a challenge. Patients’
symptomatology evolves over time and in many
patients it may be reasonable to conclude they
have a different condition early in their course
such as RA or a non-specific skin disorder. In add-
ition, many very early features may be non-specific
and individually will not raise the possibility of the
diagnosis. A recent UK study showed that in the
five years prior to diagnosis there is a higher con-
sultation rate amongst patients who are eventually
diagnosed as SLE. However, not all consultation
could be attributed to features of SLE and many
were non-specific such as fatigue and arthralgias.8
Our survey noting a time to diagnosis of more than
six years found that this time remains steady in
recent decades suggesting further work is needed
to raise awareness of SLE and related conditions
both amongst health care professionals in the UK
and amongst patients to recognize the early symp-
toms and signs of the disease.
Once the diagnosis is confirmed, there is a need
to address symptoms that are important to the indi-
vidual patient including fatigue/weakness and joint
pain. In the context of a high reported use of stand-
ard therapies, these observations demonstrate that
many of the symptoms are not fully addressed by
usual treatments. From a patient perspective, com-
monly used treatments in SLE are falling short of
managing the disease and some may even be con-
tributing to residual symptoms.9 The shortfall in
conventional therapy controlling symptoms is also
reflected in 32% of patients reporting use of alter-
native therapies including acupuncture, massage
and reflexology. Further research is therefore
needed to focus on potential causes of these symp-
toms and also to develop newer, more effective,
therapies. In addition, more consultation time per
patient may be needed to monitor and address
potential exacerbating factors for these symptoms.
Establishing new biological and non-biological
therapies remains the subject of intense ongoing
research. Assessing additional adjunctive therapies
is also likely to have a role to play in the lupus
population as a whole. For instance, there is evi-
dence that low-dose dietary supplementation with
Figure 2 Alternative therapies sought by patients.
omega-3 fish oils in SLE may have a therapeutic
effect on disease activity and may also improve
endothelial function and reduce oxidative stress.10
Likewise, the addition of vitamin D supplementa-
tion to standard SLE therapy may improve disease
activity and ameliorate inflammatory and haemo-
static markers and may also have favourable effects
on cardiovascular risk.11,12 Others have noted
improvements with exercise regimens in SLE, a
modality not specifically enquired about in this
survey.13 Complementary and alternative medicines
(CAM) are not considered to be part of conven-
tional medicine yet there is a need to develop an
evidence base to support those with true efficacy in
SLE disease management.14
We found almost three-quarters of individuals
had problems that limit their ability to carry out
their usual daily activities. Indeed, only 15% of
individuals worked full time with over 50% receiv-
ing some form of benefits and almost one-half of
retirees retiring on medical grounds. This highlights
that SLE symptoms impact directly on an individ-
ual’s ability to maintain employment, contributing
to a high societal burden across both direct health
costs and indirect costs of social care. At an indi-
vidual level, many patients also require day-to-day
support not only from health care professionals but
also from a partner, family member and friends. A
holistic approach is therefore required which
encompasses regular support from health care pro-
fessionals, psychological support such as counsel-
ling, exercise, diet and evidence-based alternative
therapies.
This survey highlights the range and frequency
of symptoms difficult to live with on a daily basis
and support areas needing further research to
improve patients’ well-being. SLE is a complex dis-
ease with multiple presentations and with numer-
ous symptoms that may overlap with other
conditions. Clinical management involves consider-
ation of the interaction of lupus drugs and medica-
tions for other conditions. Thus careful monitoring
both of clinical and patient-reported outcomes is
key to better supporting individuals with SLE and
managing the impact on their daily lives effectively.
Health care providers should aim to treat the
aspects of disease that have a more direct effect
on individual’s quality of life and furthermore con-
sider the impact upon quality of life when making
treatment decisions.
We recognize limitations of this survey. For
instance, self-reported patient recall is not formally
valid for diagnosis, although the complicated
nature of the disease and the nature of the support
group suggest it is likely that patients completing
the questionnaire do have SLE or some variant of
the disease. In particular, the distribution of thera-
pies used is similar to other UK cohorts.15 In add-
ition, individuals who participated were more likely
to be motivated individuals than individuals declin-
ing. As such there is likely to be some bias in those
who responded which we could not address, as
there was no access to the characteristics of the
non-respondents. Nevertheless, the distribution of
symptoms and limitations described were similar to
observations from more formal studies.16–18
Individuals were members of a patient support
group, already a motivated cohort potentially
better informed about their disease. The ethnic
mix of the sample was not fully representative of
the UK SLE population. In a recent survey of the
incidence and prevalence of SLE in the UK (1999–
2012), individuals of Black Caribbean ethnicity had
a significantly higher incidence of SLE (31.46/
100,000) in comparison to White individuals
(6.73/100,000).19 Nevertheless the differences
found by our survey between different ethnic
groups as well as between gender groups are still
likely to be valid overall. We accept however that
more research and better communication is there-
fore needed in, for example, Afro-Caribbean,
Chinese and Indo-Asian populations in which this
disease is more common.
In summary, our survey of a large contemporary
UKSLEpopulation shows that the diagnosis of SLE
remains a challenge with a long time from early
symptoms before making a formal diagnosis and
many patients having alternative diagnoses made
prior to SLE being confirmed.We also note a signifi-
cant unmet need in controlling symptoms important
to patients such as pain and fatigue. Residual symp-
toms contribute to significant limitations in daily
living, work loss and a need for ongoing support
from others as well as seeking unproven complemen-
tary therapies. This survey suggests a clear agenda
for further patient-focused research to improve
awareness of SLE, identify better, more effective
therapies and improve support for patients to
improve overall quality of life.
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